ArticleMedicine2026
Association between dynamic serum lactate dehydrogenase levels and functional outcome after endovascular therapy for acute ischemic stroke: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To investigate the dynamic changes in serum lactate dehydrogenase (LDH) levels and their association with 90-day functional outcome in patients with large vessel occlusion acute ischemic stroke (LVO-AIS) who underwent endovascular therapy (EVT). This retrospective cohort study consecutively enrolled 402 patients with LVO-AIS who underwent EVT at a comprehensive stroke center between January 2019 and November 2024. Serum LDH levels were measured at baseline, on postoperative day 1, and on postoperative day 3. The primary endpoint was poor functional outcome at 90 days, defined as a modified Rankin Scale score of 3 to 6. Multivariable logistic regression analysis was performed to evaluate the independent association between LDH levels and functional outcome. Receiver operating characteristic (ROC) curves were constructed to assess discriminative performance. A total of 244 patients (60.7%) had poor functional outcome at 90 days. Serum LDH levels were significantly higher in the poor outcome group than in the favorable outcome group across all time points: baseline, 216 vs 201 U/L (P = .004); postoperative day 1, 227 vs 202 U/L (P < .001); and postoperative day 3, 286 vs 219 U/L (P < .001). ROC analysis demonstrated that postoperative day 3 LDH had the best discriminative performance (AUC = 0.72), surpassing that of baseline LDH (AUC = 0.59) and postoperative day 1 LDH (AUC = 0.61). In the fully adjusted model, each 10 U/L increase in postoperative day 3 LDH was associated with a 4% increase in the odds of poor functional outcome (adjusted OR = 1.04; 95% CI, 1.02-1.06; P < .001). Quartile analysis further confirmed a dose-response relationship: compared with the lowest quartile (Q1: <205 U/L), the highest quartile (Q4: >337 U/L) was associated with a significantly elevated risk of poor outcome (adjusted OR = 3.63; 95% CI, 1.71-7.72; P < .001). Among patients with LVO-AIS who underwent EVT, serum LDH level on postoperative day 3 was independently associated with poor functional outcome at 90 days. As a readily available and routinely measured laboratory marker, dynamic LDH monitoring may provide supplementary information for early post-EVT risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.